このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cyxone マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Kjell Stenberg

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	1.1yrs

経営陣の近況

Recent updates

Here's Why We're Not Too Worried About Cyxone's (STO:CYXO) Cash Burn Situation

Dec 12

We Think Cyxone (STO:CYXO) Can Afford To Drive Business Growth

Aug 29

CEO（最高経営責任者

Kjell Stenberg (72 yo)

less than a year

在職期間

Dr. Kjell G. Stenberg, Ph D., is one of the Co-Founders and has been the Chief Executive Officer of Cyxone AB (publ) since April 22, 2024. He previously served as Chief Executive Officer of Cyxone AB (publ...

取締役

名称	ポジション	在職期間	報酬	所有権
Bert Junno	Director	no data	SEK 875.00k	0.78% SEK 184.9k
Christian Gruber	Chairman of the Scientific Advisory Board	no data	データなし	データなし
Maarten Kraan	Senior Scientific Advisor	3.9yrs	データなし	データなし
Rikard Holmdahl	Senior Scientific Advisor	less than a year	データなし	データなし
Michael Oredsson	Chairman	1.1yrs	データなし	0.29% SEK 69.5k
Andrew Scorey	Director	1.1yrs	データなし	0.29% SEK 69.5k
Jurgen Reess	Director	1.1yrs	データなし	データなし

1.1yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: CYXOの取締役会は経験豊富ではない ( 1.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Cyxone マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Cyxone AB (publ) Announces Chief Executive Officer Changes

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Recent updates

New major risk - Share price stability

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.062 loss in 1Q 2023)

Cyxone AB (publ) Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Financial position

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Cyxone AB (publ) to Report Q4, 2024 Results on Feb 25, 2025

New major risk - Revenue and earnings growth

Cyxone AB (publ) to Report Q3, 2023 Results on Nov 21, 2023

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA

Cyxone AB (Publ) Advances the Patent Portfolio for Rabeximod

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone (publ) Receives Ethical and Regulatory Approval from Hungary to Start Clinical Phase 2b Study in RA

Price target decreased to kr4.20

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (publ) Receives Regulatory Approval to Start Clinical Phase 2B Study in RA

Cyxone AB (Publ) Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (Publ) Announces CFO Changes

Cyxone AB (publ) to Report Q3, 2022 Results on Oct 27, 2023

Cyxone Files Submission to Start Clinical Phase 2B Study in Poland and Georgia

Cyxone Receives Pre-IND Response from the US FDA regarding RA study

Cyxone (Publ) Files Regulatory Submission to Start Clinical Phase 2B Study with Rabeximod

Cyxone Announces Executive Changes

Cyxone AB Announces Promising T20k/Kora Combination Therapy Efficacy in Preclinical Therapeutic Model of MS

Price target increased to kr16.00

Safety Confirmation and Observed Trends in Covid-19 Study Build Further Confidence in Cyxone's Rheumatoid Arthritis Program

Cyxone (publ) Announces Resignation of Cornel Pater as Chief Medical Officer

Cyxone (publ) Reports Publication of Four Patent Applications Pertaining to its Drug Candidate Rabeximod

Cyxone (publ) Initiates Early Operations with Global Contract Research Organization to Conduct Phase 2B Trial in Rheumatoid Arthritis

Here's Why We're Not Too Worried About Cyxone's (STO:CYXO) Cash Burn Situation

Cyxone Files Patent Application with Potential to Extend Market Exclusivity of the Drug Candidate Rabeximod

Cyxone AB (Publ) Comments on the Covid-19 Study Results

Cyxone (Publ) Presents Top-Line Results from A Phase 2 Study of Rabeximod in Covid-19 Patients

Cyxone AB (Publ) Expects to Communicate Top-Line Results from A Recently Concluded Phase 2 Trial of Its Drug Candidate Rabeximod in Covid-19 Patients

We Think Cyxone (STO:CYXO) Can Afford To Drive Business Growth

CFO & Interim CEO Ola Skanung has left the company

Cyxone Announces Rabeximod in Covid-19 Phase 2 Trial Closed and Data to Be Reports in Third Quarter

Cyxone Explores Expanding into New Regions to Mitigate Potential Delay in Covid-19 Trial Completion

Chief Operating Officer has left the company

Cyxone Joins Forces with Leading Rheumatoid Arthritis Expert

Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K

Cyxone AB (publ) to Report Q4, 2021 Results on Feb 11, 2022

Cyxone (publ.) Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod

Cyxone AB (publ), Annual General Meeting, Jun 03, 2021

Cyxone AB (publ) Files an IND in the US with Rabeximod Following Positive Feed-Back from Pre-IND Meeting with the FDA

New 90-day low: kr5.03

Cyxone AB (publ) Files Patent Application to Extend Exclusivity of Rabeximod

New 90-day low: kr5.51

Cyxone Announces Expanded Plans for Rabeximod

New 90-day low: kr5.52

Cyxone AB (Publ) Revises the Development Plan for Rabeximod

New 90-day high - kr7.48

CEO（最高経営責任者

在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04